Cosciens Biopharma Files 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: May 20, 2025 · CIK: 1113423
| Field | Detail |
|---|---|
| Company | Cosciens Biopharma INC. (CSCIF) |
| Form Type | 6-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Cosciens Biopharma (fka Aeterna Zentaris) filed a 6-K on 5/20/25. Nothing major, just routine reporting.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on May 20, 2025, reporting for the month of May 2025. The company, formerly known as Aeterna Zentaris Inc., is a foreign private issuer. Its principal executive offices are located in Toronto, Ontario, Canada.
Why It Matters
This filing indicates ongoing reporting requirements for Cosciens Biopharma Inc. as a foreign private issuer, providing transparency to investors.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal representative
- 20250520 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically for reporting material information that is made public in the issuer's home country.
What was Cosciens Biopharma Inc. formerly known as?
Cosciens Biopharma Inc. was formerly known as Aeterna Zentaris Inc.
When was this Form 6-K filed?
This Form 6-K was filed on May 20, 2025.
Where are Cosciens Biopharma Inc.'s principal executive offices located?
Cosciens Biopharma Inc.'s principal executive offices are located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does Cosciens Biopharma Inc. file annual reports under Form 20-F or 40-F?
Cosciens Biopharma Inc. files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 20, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).